Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer

Fig. 1

BluePrint standard subtypes and clinical variables a Total group, b Hormone receptor-negative disease, c Hormone receptor-positive disease, d Node-negative disease, e Node-positive disease, f HER2 immunohistochemistry 1–2 + tumors, g HER2 immunohistochemistry 3 + tumors. HR hormone receptor, cN0 clinically node-negative, cN + clinically node-positive, HER2 IHC HER2 immunohistochemistry score

Back to article page